banner-image

Prof Rory McCrimmon presents Practical considerations for the management of impaired awareness of hypoglycaemia

 

Hypoglycaemia is a common and serious complication of diabetes, particularly affecting your patients on insulin therapy. It can have serious acute and long-term impacts.1,2

Watch Prof Rory McCrimmon dive deeper into topics around understanding the mechanisms of hypoglycaemia and strategies to help reduce the risk of hypoglycaemia.
 

References: 1.
 https://hypo-resolve.eu/project (accessed 15th April 2019). 2. Zhong VW et al. Diabetes Care 2017;40:1651–60.

Toujeo

Toujeo®

(insulin glargine 300 units/mL) 
PBS Information:
Toujeo SoloStar is listed on the PBS as a long-acting insulin analogue for the treatment of adults with type 1 and type 2 diabetes.

Please review Product Information before prescribing Toujeo.

Further information is available on request from the supplier.

Toujeo® and SoloStar® are registered trademarks of sanofi-aventis australia pty ltd. Sanofi-Aventis Australia PTY LTD trading as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12–24 Talavera Road, Macquarie Park, NSW 2113. 

SAANZ.TJO.19.06.0305. DIB0036. Date of preparation: June 2019.